Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 77.5% in July

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 4,548 shares, a decline of 77.5% from the June 30th total of 20,244 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 29,911 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Cardio Diagnostics Stock Down 4.9%

CDIO opened at $1.55 on Friday. The firm has a market cap of $4.59 million, a PE ratio of -0.46 and a beta of 2.23. The business has a fifty day simple moving average of $1.87 and a 200-day simple moving average of $2.18. Cardio Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $7.91.

Cardio Diagnostics (NASDAQ:CDIO) last announced its earnings results on Friday, May 15th. The company reported ($0.63) earnings per share (EPS) for the quarter. Cardio Diagnostics had a negative return on equity of 78.82% and a negative net margin of 36,950.00%.

Institutional Trading of Cardio Diagnostics

Several institutional investors and hedge funds have recently bought and sold shares of CDIO. Citadel Advisors LLC purchased a new stake in Cardio Diagnostics during the third quarter valued at about $79,000. DRW Securities LLC lifted its position in shares of Cardio Diagnostics by 122.8% in the 4th quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock valued at $110,000 after acquiring an additional 22,298 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Cardio Diagnostics in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.